[Federal Register Volume 68, Number 134 (Monday, July 14, 2003)]
[Notices]
[Page 41661]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-17715]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 28, 2003, Cambrex North 
Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, 
North Brunswick, New Jersey 08902, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed 
below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methamphetamine (1105)......................  I
N-Ethylamphetamine (1475)...................  I
Tetrahydrocannabinols (7370)................  I
2,5-Dimethoxyamphetamine (7396).............  I
3,4-Methylenedioxyamphetamine (7400)........  I
4-Methoxyamphetamine (7411).................  I
Amphetamine (1100)..........................  II
Methylphenidate (1724)......................  II
Morphine (9300).............................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The firm plans to manufacture the listed controlled substances for 
distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must filed no later than September 
13, 2003.

    Dated: June 25, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-17715 Filed 7-11-03; 8:45 am]
BILLING CODE 4410-09-M